Merck’s $53 Terns Offer Priced for Perfection—But Shareholders Suspect a Missed Opportunity

Merck's $53-per-share cash offer for Terns, valued at approximately $6.7 billion, is a transaction that has caught the market off guard. The deal, expected to close in the second quarter of 2026, is framed by a central puzzle: the price being paid is remarkably low. The offer represents a mere 6% premium over Terns' closing price on Tuesday, March 24, 2026. This figure is among the lowest premiums paid for a publicly traded drugmaker since at least 2018, according to industry data.

This is the prevailing sentiment. The market's reaction is one of surprise and skepticism, not celebration. The low premium stands in stark contrast to the high expectations for Terns' lead candidate, TERN-701. The drug, an investigational oral treatment for chronic myeloid leukemia, has generated significant excitement after showing promising early results. Some analysts have forecast peak sales estimates that effectively surpass the net $5.7 billion Merck is paying, even after accounting for Terns' cash reserves. In that light, the 6% bump looks like a missed opportunity.

The skepticism is amplified by legal scrutiny. Multiple shareholder rights law firms have launched investigations into the acquisition, alleging potential breaches of fiduciary duty and an unfair price for public shareholders. This legal overhang suggests a segment of the investor base believes the deal undervalues the company, adding another layer of uncertainty to the transaction's path to completion.

The central question for investors now is whether this low premium already reflects the market's high expectations for TERN-701, leaving little room for upside. The deal price appears to be priced for perfection, assuming the drug's potential is fully realized. Any stumble in its clinical development or a failure to capture the anticipated market share could quickly make the $53 offer look inadequate.

Assessing the Target: Peak Sales Forecasts vs. Deal Value

The scientific rationale for TERN-701 is compelling. The drug has shown "unprecedented ~60% 6-month MMR across hard-to-treat subgroups" in early trials, a profile that key opinion leaders have lauded as having "best-in-class potential." This efficacy, coupled with a favorable safety profile, has driven a significant re-rating of Terns' stock. The company's 52-week high of $53.17, reached earlier this month, is a direct reflection of the market's high expectations for the drug's commercial potential.

Analyst projections have been aggressive. Truist Securities, for instance, recently raised its price target to $35.00 and increased its peak adjusted sales forecast for TERN-701 to $1.6 billion. More broadly, the evidence indicates that analysts have forecast peak annual sales estimates for TERN-701 that effectively surpass the net $5.7 billion Merck is paying, when accounting for Terns' cash reserves. This creates a clear expectations gap: the market had already priced in a blockbuster future for the drug.

Viewed through this lens, Merck's $53-per-share offer appears to be priced for perfection. The deal value assumes TERN-701 will not only meet but likely exceed these lofty sales projections. The low 6% premium suggests the market sees little room for error. If the drug hits its peak sales target, the acquisition could look like a bargain. But if development faces any setbacks or market uptake is slower than anticipated, the current price may already reflect the best-case scenario, leaving shareholders with limited upside. The key question is whether the deal price already captures the market's optimism, leaving little room for the drug to simply meet expectations.

The Risk/Reward Asymmetry: Catalysts and Contingencies

The setup creates a clear asymmetry. The risk of a competing bid is real, but the reward of the current $53 offer is already priced for perfection if the drug meets expectations.

On one side, the catalyst for higher value is a competing offer. Leerink Partners analyst Andrew Berens has stated the deal price "vastly underestimates the potential" for TERN-701. He argues that a different buyer paying a "reasonable multiple" of 1.5 to two times peak forecasted sales would represent a "meaningful premium to the current bid." This view is supported by the fact that Terns is "well-capitalized with runway into 2028". This financial stability gives the company time to pursue alternative options if a better offer emerges. Rivals like AbbVie or Bristol Myers Squibb, which have significant oncology portfolios and cash, could be interested in a competing bid, especially if they see the drug's potential as undervalued.

On the other side, the primary catalyst for the current deal is its completion. The tender offer is expected to close in the second quarter of 2026. However, the ongoing shareholder investigations could act as a catalyst themselves. While they are more likely to lead to increased disclosures about the deal's fairness, they could, less commonly, pressure Merck into improving its offer. The legal overhang adds a layer of uncertainty that could delay or complicate the process.

The key question is the asymmetry. The risk of a competing bid introduces a potential upside that is not reflected in the current $53 price. Yet, the reward of that upside is contingent on a rival stepping in, which is not guaranteed. Meanwhile, the current offer is already priced for perfection, assuming TERN-701 hits its peak sales targets. If the drug merely meets expectations, the $53 price may already be adequate. The real risk is that the drug underperforms, leaving shareholders with a deal that was priced for a best-case scenario.

Broader Context: Biotech M&A and the Pricing of Innovation

Merck's Terns deal must be viewed against a backdrop of a market that has been aggressively pricing innovation. In 2025, biopharma M&A activity saw a decisive rebound, with aggregate deal value more than doubling, jumping by +133% to reach $133Bn for the full year. This surge indicates a strong appetite for new assets, even as the average deal size remained in the $2.7 billion range. The trend was defined by fierce competition for sought-after pipelines, exemplified by the bidding war for Metsera's obesity assets, where offers escalated from $4.9 billion to $10 billion. In this environment, the $6.7 billion Terns transaction fits the pattern of a major acquisition, but the 6% premium stands out as notably low.

This low premium is a strategic anomaly in a hot market. It contrasts sharply with the typical structure of recent large deals, which often incorporate contingent value rights (CVRs) to bridge perceived value gaps and balance risk. The fact that Merck is paying a straightforward cash price with such a minimal bump suggests either a high degree of confidence in TERN-701's trajectory or a deliberate move to secure the asset quickly before a potential rival emerges. The consensus view among analysts, a "Moderate Buy" with a $56.90 target, reflects this cautious optimism. It signals that the market sees value in the deal but remains skeptical of the low premium, implying that the current price may already capture much of the drug's potential upside.

The key question is whether this is a disciplined pricing strategy or a missed opportunity. In a market where deals are being structured to share risk, a flat, low-premium offer for a drug with "best-in-class potential" appears unusual. It could be a calculated bet by Merck that the asset's value is already fully reflected in Terns' stock price, leaving little room for error. Yet, as Leerink Partners notes, a different buyer paying a "reasonable multiple" of peak sales would represent a "meaningful premium." The asymmetry remains: the low premium prices the deal for perfection, but the broader M&A trend suggests that perfection often commands a higher price.